메뉴 건너뛰기




Volumn 4, Issue 1, 2013, Pages 29-34

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: Implications for personalized medicine

Author keywords

AKT1; Cancer; Mutation; Personalized; Therapy

Indexed keywords

AKT1 PROTEIN; CELL PROTEIN; PROTEIN KINASE B; PROTEIN PRAS40; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

EID: 84875799044     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.755     Document Type: Article
Times cited : (34)

References (16)
  • 3
    • 53949099847 scopus 로고    scopus 로고
    • Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells
    • Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat. 2008;112:217-227.
    • (2008) Breast Cancer Res Treat , vol.112 , pp. 217-227
    • Zhang, H.1    Liu, G.2    Dziubinski, M.3    Yang, Z.4    Ethier, S.P.5    Wu, G.6
  • 8
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive portraits of human breast tumors
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network. Comprehensive portraits of human breast tumors. Nature. 2012;490:61-70.
    • (2012) Nature , vol.490 , pp. 61-70
  • 9
    • 56749168073 scopus 로고    scopus 로고
    • Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain
    • Landgraf KE, Pilling C, Falke JJ. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry. 2008;47:12260-12269.
    • (2008) Biochemistry , vol.47 , pp. 12260-12269
    • Landgraf, K.E.1    Pilling, C.2    Falke, J.J.3
  • 14
    • 84875795193 scopus 로고    scopus 로고
    • Modeling cetuximab clinical trial by conducting in vivo efficacy evaluation in large panel CRC patient-derived xenograft (PDX) models
    • Chen D, Yang M, Deng J, Song X, Cai J, Chen T, Chen Y, Li H. Modeling cetuximab clinical trial by conducting in vivo efficacy evaluation in large panel CRC patient-derived xenograft (PDX) models. Molecular Cancer Therapeutics. 2011;10:C113.
    • (2011) Molecular Cancer Therapeutics , vol.10
    • Chen, D.1    Yang, M.2    Deng, J.3    Song, X.4    Cai, J.5    Chen, T.6    Chen, Y.7    Li, H.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.